Alnylam Pharmace. buy Sanford C. Bernstein
Start price
07.01.25
/
50%
€228.10
Target price
07.01.26
€298.93
Performance (%)
56.51%
Price
09.12.25
€357.00
Summary
This prediction is currently active. The BUY prediction by Sanford_C__Bernstein for Alnylam Pharmace. has seen massive gains of 56.51%. This prediction currently runs until 07.01.26. The prediction end date can be changed by Sanford_C__Bernstein at any time. Sanford_C__Bernstein has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -8.836% | -8.836% |
| iShares Core DAX® | 1.659% | 1.586% |
| iShares Nasdaq 100 | 0.381% | 1.900% |
| iShares Nikkei 225® | 2.102% | -1.377% |
| iShares S&P 500 | 0.221% | 1.258% |
Comments by Sanford_C__Bernstein for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Sanford C. Bernstein from $314.00 to $310.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat